David Badawi Sells 3,829 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 3,829 shares of the business's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $3.26, for a total transaction of $12,482.54. Following the transaction, the chief technology officer now directly owns 1,749,541 shares in the company, valued at $5,703,503.66. The trade was a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

David Badawi also recently made the following trade(s):

• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Trading Down 2.1 %

NASDAQ SGHT traded down $0.07 on Friday, reaching $3.25. The company had a trading volume of 294,351 shares, compared to its average volume of 244,208. The firm has a market cap of $164.95 million, a price-to-earnings ratio of -3.19 and a beta of 2.57. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. Sight Sciences, Inc. has a fifty-two week low of $3.16 and a fifty-two week high of $8.45. The business has a 50 day moving average of $3.82 and a two-hundred day moving average of $5.52.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $20.16 million for the quarter, compared to analysts' expectations of $20.41 million. Analysts forecast that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Institutional Investors Weigh In On Sight Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. American Century Companies Inc. lifted its holdings in shares of Sight Sciences by 31.1% during the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company's stock worth $240,000 after acquiring an additional 8,527 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in Sight Sciences by 5.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company's stock valued at $1,174,000 after purchasing an additional 10,000 shares during the period. Rhumbline Advisers raised its holdings in shares of Sight Sciences by 40.1% during the second quarter. Rhumbline Advisers now owns 40,811 shares of the company's stock valued at $272,000 after acquiring an additional 11,671 shares in the last quarter. SG Americas Securities LLC bought a new stake in Sight Sciences in the third quarter valued at $75,000. Finally, Geode Capital Management LLC lifted its position in shares of Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company's stock worth $4,941,000 after purchasing an additional 12,709 shares during the period. 55.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on SGHT shares. Citigroup reduced their target price on shares of Sight Sciences from $5.80 to $4.60 and set a "neutral" rating on the stock in a research note on Wednesday, December 11th. Lake Street Capital cut shares of Sight Sciences from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $10.00 to $5.00 in a research note on Monday, November 4th. Morgan Stanley cut their target price on shares of Sight Sciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Monday, November 11th. Piper Sandler restated a "neutral" rating and set a $5.50 price target (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $5.12.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.